Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

GOCO vs RNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RNA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–0 Matrix Metrics)

RNA Overall Winner 6-Pillar Tally: GOCO 1 – 4 RNA (1 Tie) Matrix Metrics: GOCO 0 – 7 RNA

As of Nov 17, 2026, Avidity Biosciences, Inc. (RNA) is the stronger overall head-to-head candidate over GoHealth, Inc. (GOCO) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GOCO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.30 (N/M Forward P/E, -292.0% operating margin), whereas RNA carries 47.4/100 (HOLD) at $6.51 (N/M Forward P/E, -194.8% operating margin).

  • Technical & Structure Timing Caution: GOCO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.9); meanwhile RNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GOCO vs RNA
GOCO NASDAQ
GoHealth, Inc. Class A Common Stock
Insurance Agents, Brokers & Service
$0.30
+5.14% 1D
Market Cap $8.5M
TTM Revenue $153M
Forward P/E N/M
Beta / 30D Vol 2.15β · 201% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 48.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -32.2%), weak momentum, RSI 24
RSI-14: 23.9 · SMA20: $0.59 · SMA50: $0.88
RNA NASDAQ Head-to-Head Winner
Avidity Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$6.51
+1.32% 1D
Market Cap $162.0M
TTM Revenue $39M
Forward P/E N/M
Beta / 30D Vol 1.05β · 63% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 61.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.0%), weak momentum, RSI 26
RSI-14: 26.5 · SMA20: $8.04 · SMA50: $8.40

6-Pillar Scorecard Institutional Category Breakdown (GOCO 1 – 4 RNA)

Columns: Metric · GOCO · RNA
1. Valuation Multiples GOCO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.1x N/M
2. Growth & Scale RNA
Revenue Growth (YoY) -94.6% +24.2%
Earnings Growth (YoY) +424.1% +0.0%
TTM Revenue (USD) $153M $39M
Market Cap $8.5M $162.0M
3. Profitability & Quality RNA
Gross Margin 57.3% -14.0%
Operating Margin -292.0% -194.8%
Net Profit Margin -189.7% -180.9%
Return on Equity (ROE) -289.9% -95.0%
4. Balance Sheet & Cash Flow RNA
Cash Generation (TTM) -$148M EBITDA -$73M
Cash Flow Margin -96.9% EBITDA Mgn N/A
Net Cash / Leverage $0.13 Book/Sh · -289.9% ROE $265M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RNA
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 0.9% (2nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Insurance Brokers Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GOCO (0) vs RNA (7)
Institutional Metric GOCO RNA Criterion Row Edge
Market Capitalization
Scale
$8.5M $162.0M Larger Scale RNA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-94.6% +24.2% Higher Growth RNA
Operating Margin (TTM)
Profitability
-292.0% -194.8% Higher Margin RNA
Net Profit Margin
Profitability
-189.7% -180.9% Higher Margin RNA
Return on Equity (ROE)
Capital Efficiency
-289.9% -95.0% Higher ROE RNA
52-Week Range Position
Momentum
0% ($0–$7) 0% ($6–$73) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
2.15β · 201% Vol 1.05β · 63% Vol Lower Realized Risk RNA
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 47.4 / 100 (HOLD) Higher Composite RNA
Trailing 12M Revenue (USD)
Operating Scale
$153M $39M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
57.3% -14.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$148M EBITDA ($0.13 Book/Sh · -289.9% ROE) -$73M ($265M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RNA +60.77 pp
GOCO: -64.69% · RNA: -3.92%
3M Horizon RNA +73.98 pp
GOCO: -81.52% · RNA: -7.54%
6M Horizon RNA +7.49 pp
GOCO: -89.63% · RNA: -82.14%
1Y Horizon RNA +6.29 pp
GOCO: -88.29% · RNA: -82.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GOCO vs RNA. Trailing 12-month operating profitability (GOCO -292.0% vs RNA -194.8%) and valuation multiples (GOCO N/M vs RNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GOCO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$153M
Gross Margin57.3%
Op. Margin-292.0%
ROE / Fwd P/E-289.9% · N/M
RNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$39M
Gross Margin-14.0%
Op. Margin-194.8%
ROE / Fwd P/E-95.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GOCO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GOCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RNA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.9%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GOCO Moat Profile Cyclical / Execution-Driven Positioning
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $8.5M market capitalization and -292.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $162.0M market capitalization and -194.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GOCO vs RNA Key Questions & Quantitative Answers

As of Nov 17, 2026, Avidity Biosciences, Inc. (RNA) is the stronger overall head-to-head candidate over GoHealth, Inc. (GOCO) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GOCO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.30 (N/M Forward P/E, -292.0% operating margin), whereas RNA carries 47.4/100 (HOLD) at $6.51 (N/M Forward P/E, -194.8% operating margin). Technical & Structure Timing Caution: GOCO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.9); meanwhile RNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RNA leads the Growth & Scale pillar: GOCO posts -94.6% YoY revenue growth and +424.1% YoY earnings growth on $153M TTM revenue (57.3% gross margin, -292.0% operating margin), compared with RNA at +24.2% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-14.0% gross margin, -194.8% operating margin). On trailing 12-month operating scale, GOCO generates $153M in USD-normalized revenue versus $39M for RNA. In operating R&D and SG&A reinvestment, GOCO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RNA.

GOCO screens cheaper on headline valuation multiples. GOCO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-96.9% EBITDA margin), whereas RNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GOCO (-289.9% ROE) versus RNA (-95.0% ROE) capital efficiency.

In options market volatility and institutional positioning, GOCO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.15β · 201% Vol realized risk). By comparison, RNA carries 0.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.